全球细胞治疗市场规模、份额、趋势和成长分析报告（2026-2034年）

细胞治疗市场预计将从 2025 年的 3,058 万美元成长到 2034 年的 1.5242 亿美元，2026 年至 2034 年的复合年增长率为 19.54%。

再生医学和免疫疗法的突破性进展正推动全球细胞疗法市场快速成长。细胞治疗方法正越来越多地用于治疗癌症、自体免疫疾病和遗传性疾病。不断扩大的临床研究和监管核准正在加速其在整个医疗保健系统中的商业性化应用。

成长要素包括慢性病增多、干细胞研究进展、生技领域投资增加。 CAR-T疗法和个人化治疗方案正在改变癌症的治疗方式。然而，高昂的治疗费用和复杂的生产流程仍然是其广泛应用的主要挑战。

展望未来，可扩展製造技术的创新和监管流程的改进有望加速市场成长。生物技术公司与医疗服务提供者之间的策略合作可望扩大全球应用范围。随着研究的不断深入，细胞治疗领域有望迎来显着扩张。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球细胞疗法市场：依技术划分

• 市场分析、洞察与预测
• 体细胞技术
• 细胞永生化技术
• 病毒载体技术
• 基因组编辑技术
• 细胞可塑性技术
• 三维技术

第五章 全球细胞疗法市场：按类型划分

• 市场分析、洞察与预测
• 自体移植
• 同种异体移植

第六章 全球细胞治疗市场：依细胞类型划分

• 市场分析、洞察与预测
• 干细胞
• 非干细胞

第七章 全球细胞疗法市场：依细胞来源划分

• 市场分析、洞察与预测
• 诱导性多能干细胞
• 骨髓
• 脐带血衍生细胞
• 脂肪组织
• 神经干细胞

第八章 全球细胞治疗市场：依应用划分

• 市场分析、洞察与预测
• 肌肉骨骼系统
• 循环系统
• 消化器官系统
• 神经系统
• 肿瘤学
• 皮肤科
• 伤口与创伤
• 眼科
• 其他的

第九章 全球细胞治疗市场：依最终用户划分

• 市场分析、洞察与预测
• 医院和诊所
• 再生医学中心
• 诊断与研究中心
• 其他的

第十章 全球细胞治疗市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第十一章 竞争格局

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十二章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Kolon TissueGene Inc
  • JCR Pharmaceuticals Co. Ltd
  • Medipost
  • Stemedica Cell Technologies Inc
  • NuVasive Inc
  • Castle Creek Biosciences Inc
  • Cellectis
  • BioNTech IMFS
  • Pluri Biotech Ltd
  • Praxis Healthcare & Pharmaceuticals PVT. LTD
  • Pharmicell Co. Ltd

The Cell Therapy Market size is expected to reach USD 152.42 Million in 2034 from USD 30.58 Million (2025) growing at a CAGR of 19.54% during 2026-2034.

The global cell therapy market is growing rapidly due to breakthroughs in regenerative medicine and immunotherapy. Cell-based treatments are increasingly used to address cancer, autoimmune diseases, and genetic disorders. Expanding clinical research and regulatory approvals are strengthening commercial adoption across healthcare systems.

Growth drivers include rising prevalence of chronic diseases, advancements in stem cell research, and increasing investment in biotechnology. CAR-T therapies and personalized treatment approaches are transforming oncology care. However, high treatment costs and complex manufacturing processes remain key challenges for widespread accessibility.

Looking forward, technological innovation in scalable manufacturing and improved regulatory pathways will accelerate market growth. Strategic collaborations between biotech firms and healthcare providers are expected to expand global availability. The cell therapy sector is poised for substantial expansion as research continues to advance.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Technology

• Somatic Cell Technology
• Cell Immortalization Technology
• Viral Vector Technology
• Genome Editing Technology
• Cell Plasticity Technology
• Three-Dimensional Technology

By Type

• Autologous
• Allogeneic

By Cell Type

• Stem Cell
• Non-Stem Cell

By Cell Source

• Induced Pluripotent Stem Cells
• Bone Marrow
• Umbilical Cord Blood-Derived Cells
• Adipose Tissues
• Neural Stem Cells

By Application

• Musculoskeletal
• Cardiovascular
• Gastrointestinal
• Neurological
• Oncology
• Dermatology
• Wounds and Injuries
• Ocular
• Others

By End-User

• Hospitals and Clinics
• Regenerative Medicine Centres
• Diagnostic and Research Centres
• Others

COMPANIES PROFILED

• Kolon TissueGene Inc, JCR Pharmaceuticals Co Ltd, Medipost, Stemedica Cell Technologies Inc, NuVasive Inc, Castle Creek Biosciences Inc, Cellectis, BioNTech IMFS, Pluri Biotech Ltd, Praxis Healthcare Pharmaceuticals PVT LTD, Pharmicell Co Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CELL THERAPY MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Technology
• 4.2. Somatic Cell Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Cell Immortalization Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Viral Vector Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Genome Editing Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Cell Plasticity Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Three-Dimensional Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CELL THERAPY MARKET: BY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Type
• 5.2. Autologous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Allogeneic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CELL THERAPY MARKET: BY CELL TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Cell Type
• 6.2. Stem Cell Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Non-Stem Cell Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CELL THERAPY MARKET: BY CELL SOURCE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Cell Source
• 7.2. Induced Pluripotent Stem Cells Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Bone Marrow Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Umbilical Cord Blood-Derived Cells Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Adipose Tissues Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Neural Stem Cells Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CELL THERAPY MARKET: BY APPLICATION 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Application
• 8.2. Musculoskeletal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Cardiovascular Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Gastrointestinal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Neurological Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.6. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.7. Dermatology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.8. Wounds and Injuries Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.9. Ocular Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.10. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL CELL THERAPY MARKET: BY END-USER 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast End-user
• 9.2. Hospitals and Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Regenerative Medicine Centres Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.4. Diagnostic and Research Centres Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL CELL THERAPY MARKET: BY REGION 2022-2034(USD MN)

• 10.1. Regional Outlook
• 10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.2.1 By Technology
  • 10.2.2 By Type
  • 10.2.3 By Cell Type
  • 10.2.4 By Cell Source
  • 10.2.5 By Application
  • 10.2.6 By End-user
  • 10.2.7 United States
  • 10.2.8 Canada
  • 10.2.9 Mexico
• 10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.3.1 By Technology
  • 10.3.2 By Type
  • 10.3.3 By Cell Type
  • 10.3.4 By Cell Source
  • 10.3.5 By Application
  • 10.3.6 By End-user
  • 10.3.7 United Kingdom
  • 10.3.8 France
  • 10.3.9 Germany
  • 10.3.10 Italy
  • 10.3.11 Russia
  • 10.3.12 Rest Of Europe
• 10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.4.1 By Technology
  • 10.4.2 By Type
  • 10.4.3 By Cell Type
  • 10.4.4 By Cell Source
  • 10.4.5 By Application
  • 10.4.6 By End-user
  • 10.4.7 India
  • 10.4.8 Japan
  • 10.4.9 South Korea
  • 10.4.10 Australia
  • 10.4.11 South East Asia
  • 10.4.12 Rest Of Asia Pacific
• 10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.5.1 By Technology
  • 10.5.2 By Type
  • 10.5.3 By Cell Type
  • 10.5.4 By Cell Source
  • 10.5.5 By Application
  • 10.5.6 By End-user
  • 10.5.7 Brazil
  • 10.5.8 Argentina
  • 10.5.9 Peru
  • 10.5.10 Chile
  • 10.5.11 South East Asia
  • 10.5.12 Rest of Latin America
• 10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.6.1 By Technology
  • 10.6.2 By Type
  • 10.6.3 By Cell Type
  • 10.6.4 By Cell Source
  • 10.6.5 By Application
  • 10.6.6 By End-user
  • 10.6.7 Saudi Arabia
  • 10.6.8 UAE
  • 10.6.9 Israel
  • 10.6.10 South Africa
  • 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

• 11.1. Recent Developments
• 11.2. Company Categorization
• 11.3. Supply Chain & Channel Partners (based on availability)
• 11.4. Market Share & Positioning Analysis (based on availability)
• 11.5. Vendor Landscape (based on availability)
• 11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL CELL THERAPY INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Company Profiles
  • 12.2.1 Kolon TissueGene Inc
  • 12.2.2 JCR Pharmaceuticals Co. Ltd
  • 12.2.3 Medipost
  • 12.2.4 Stemedica Cell Technologies Inc
  • 12.2.5 NuVasive Inc
  • 12.2.6 Castle Creek Biosciences Inc
  • 12.2.7 Cellectis
  • 12.2.8 BioNTech IMFS
  • 12.2.9 Pluri Biotech Ltd
  • 12.2.10 Praxis Healthcare & Pharmaceuticals PVT. LTD
  • 12.2.11 Pharmicell Co. Ltd